-Shaomeng Wang Researcher Activity Profile

Research Author Detailed Information 

Shaomeng Wang Publication Rate By Year

Shaomeng Wang has published 1 paper(s) in 2004, 2 paper(s) in 2005, 7 paper(s) in 2006, 10 paper(s) in 2007, 6 paper(s) in 2008, for a total of 26 research publications in total.

Shaomeng S Wang Author Information

LAST NAME: wang

FIRST NAME: shaomeng

INITIALS: S

AFFILIATION:

Papers

Shaomeng Wang's Publication Record

1. Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins. Year Published: 2007
Department of Internal Medicine, Comprehensive Cancer Center, and Life Sciences Institute, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109, USA.
2. p27 degradation by an ellipticinium series of compound via ubiquitin-proteasome pathway. Year Published: 2007
Division of Cancer Biology, Department of Radiation Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109-0936, USA.
3. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Year Published: 2006
Divison of Radiobiology and Molecular Environmental Research, Department of Radiation Oncology, University of Tuebingen, Tuebingen, Germany.
4. Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. Year Published: 2006
Angiogenesis Research Laboratory, Department of Restorative Sciences, School of Dentistry, University of Michigan, Ann Arbor, MI 48109-1078, USA.
5. Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein. Year Published: 2006
Comprehensive Cancer Center and Departments of Internal Medicine, Pharmacology and Medicinal Chemistry, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA.
6. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. Year Published: 2006
Comprehensive Cancer Center and Department of Internal Medicine, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109, USA.
7. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Year Published: 2006
Department of Dermatology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA.
8. Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. Year Published: 2006
Comprehensive Cancer Center, Department of Internal Medicine, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA.
9. Identification of novel neuroprotective agents using pharmacophore modeling. Year Published: 2006
Department of Neuroscience, Georgetown University Medical Center, 3970 Reservoir Road. N. W., Research Building, Rm. EP12, Washington, DC 20057, USA. fadena@georgetown.edu
10. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions. Year Published: 2007
Department of Chemistry, University of Wisconsin, Madison, Wisconsin 53706, USA.
11. Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Year Published: 2007
Department of Pharmacology, University of Michigan Medical School, 1301 MSRB III, 1150 W. Medical Center Drive, Ann Arbor, MI 48109-0632, USA.
12. Structure-based design of flavonoid compounds as a new class of small-molecule inhibitors of the anti-apoptotic Bcl-2 proteins. Year Published: 2007
Comprehensive Cancer Center and Department of Internal Medicine, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109, USA.
13. Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models. Year Published: 2007
Department of Medicinal Chemistry and the Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
14. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. Year Published: 2007
Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109, USA.
15. Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models. Year Published: 2007
Department of Medicinal Chemistry and the Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
16. Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models. Year Published: 2007
Department of Medicinal Chemistry and the Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
17. Structure-based design of potent, conformationally constrained Smac mimetics. Year Published: 2004
Departments of Internal Medicine and Medicinal Chemistry and Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA.
18. Structure-based design of potent non-peptide MDM2 inhibitors. Year Published: 2005
Departments of Internal Medicine and Medicinal Chemistry and Comprehensive Cancer Center, and Life Sciences Institute, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109, USA.
19. Chimeric (alpha/beta + alpha)-peptide ligands for the BH3-recognition cleft of Bcl-XL: critical role of the molecular scaffold in protein surface recognition. Year Published: 2005
Department of Chemistry, University of Wisconsin, Madison, Wisconsin 53706, USA.
20. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Year Published: 2008
21. Design and characterization of bivalent Smac-based peptides as antagonists of XIAP and development and validation of a fluorescence polarization assay for XIAP containing both BIR2 and BIR3 domains. Year Published: 2008
Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
22. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. Year Published: 2007
Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109, USA.
23. Acylpyrogallols as inhibitors of antiapoptotic bcl-2 proteins. Year Published: 2008
shaomeng@umich.edu.
24. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Year Published: 2008
Comprehensive Cancer Center and Department of Internal Medicine, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA.
25. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Year Published: 2008
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor MI 48109-0936, USA.
26. Acylpyrogallols as inhibitors of antiapoptotic Bcl-2 proteins. Year Published: 2008